1,35 Most importantly, four different long-acting GLP-1RAs (liraglutide, albiglutide, semaglutide and dulaglutide) have been found to the reduce risk of future major adverse cardiovascular events (MACE, including cardiovascular death, non-fatal myocardial infarction and stroke) in patients with T2D, with the other long-acting GLP-1RAs, exenatide once-weekly (exeOW) showing a trend towards reduction in MACE combined with a nominally significant reduction in overall mortality
Brussels: International Diabetes Federation
F., Metz A
Donisi, 2025
Your doctor will take a comprehensive look at your medical history, current health status, progress, and any side effects you might be experiencing
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: A randomized placebo-controlled trial with a safety extension